![](https://news.europawire.eu/wp-content/uploads/2021/12/ORIGIMM-144x144.jpg)
Origimm brings expertise in antigen discovery for immune modulation of skin microbiome-associated disorders Transaction adds to Sanofi pipeline a potential first-in-class vaccine candidate in acne vulgaris, a condition affecting millions of people worldwide Sanofi to leverage its next-generation mRNA platform to unlock … Read the full press release